Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does AMLODIPINE Cause Basal cell carcinoma? 87 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 87 reports of Basal cell carcinoma have been filed in association with AMLODIPINE (Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide). This represents 0.1% of all adverse event reports for AMLODIPINE.

87
Reports of Basal cell carcinoma with AMLODIPINE
0.1%
of all AMLODIPINE reports
22
Deaths
44
Hospitalizations

How Dangerous Is Basal cell carcinoma From AMLODIPINE?

Of the 87 reports, 22 (25.3%) resulted in death, 44 (50.6%) required hospitalization, and 24 (27.6%) were considered life-threatening.

Is Basal cell carcinoma Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for AMLODIPINE. However, 87 reports have been filed with the FAERS database.

What Other Side Effects Does AMLODIPINE Cause?

Hypotension (6,504) Toxicity to various agents (5,554) Completed suicide (5,267) Drug ineffective (4,091) Dyspnoea (3,907) Dizziness (3,536) Intentional overdose (3,427) Fall (3,215) Fatigue (3,141) Headache (2,907)

What Other Drugs Cause Basal cell carcinoma?

ADALIMUMAB (1,547) INFLIXIMAB (1,340) METHOTREXATE (1,268) RITUXIMAB (1,085) ETANERCEPT (998) ABATACEPT (852) TOCILIZUMAB (761) LENALIDOMIDE (685) HYDROXYCHLOROQUINE (662) LEFLUNOMIDE (657)

Which AMLODIPINE Alternatives Have Lower Basal cell carcinoma Risk?

AMLODIPINE vs AMLODIPINE BESILATE AMLODIPINE vs AMLODIPINE\ATORVASTATIN AMLODIPINE vs AMLODIPINE\BENAZEPRIL AMLODIPINE vs AMLODIPINE\HYDROCHLOROTHIAZIDE\OLMESARTAN AMLODIPINE vs AMLODIPINE\HYDROCHLOROTHIAZIDE\OLMESARTAN MEDOXOMIL

Related Pages

AMLODIPINE Full Profile All Basal cell carcinoma Reports All Drugs Causing Basal cell carcinoma AMLODIPINE Demographics